IP Library Granted Patent US 12,661,263
Granted Patent B2
US 12,661,263 · App. 18/000,671 · Granted Jun 23, 2026

Eye shunt system and methods

Inventors: Karanjit S. Kooner (Plano, TX); Michael A. Mong (Grapevine, TX); Ghadeer Al-Humimat (Dallas, TX); Jacob A. Awkal (Plano, TX); Hebah G. Abdallah (Carrollton, TX); Nguyen L. Le (Richardson, TX); Jamasp Azarnoosh (Dallas, TX); Peter Dirk Jan Reyntjens (Richardson, TX); Jeremy L. Warren (El Paso, TX)
Assignees: The Board Regents of The University of Texas System; THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS
A61F9/00781
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,661,263
App. No.
18/000,671
Granted
Jun 23, 2026
Kind
B2
Abstract

A shunt operable to be implanted on an eye is provided. The shunt includes a vein fluidic channel operable to be in fluid communication with an interior of the eye and operable to receive aqueous fluid from the interior of the eye. A body is fluidly coupled with the vein fluidic channel. A valve is disposed within the body and is operable to regulate intraocular pressure in the eye by opening and closing based on pressure from the aqueous fluid. A plurality of outlets are in fluid communication with the body opposite the vein fluidic channel in relation to the valve. The outlets are operable to release the aqueous fluid to the sclera of the eye.

Claims (27)

1 . A shunt operable to be implanted on an eye, the shunt comprising:

a vein fluidic channel operable to be in fluid communication with an interior of the eye and operable to receive aqueous fluid from the interior of the eye;

a body fluidly coupled with the vein fluidic channel;

a valve disposed within the body, the valve operable to regulate intraocular pressure (IOP) in the eye by opening and closing based on pressure from the aqueous fluid, wherein the valve includes two leaflets, wherein a base of each of the leaflets has a base thickness, and wherein a thickness of the two leaflets tapers towards an end opposite the base, and wherein the valve further comprises a commissure where the respective ends of the two leaflets opposite the bases of the two leaflets are configured to meet when the valve is closed;

an exit chamber configured to receive aqueous fluid exiting the valve when the valve is open; and

a plurality of outlets in fluid communication with the exit chamber, the plurality of outlets operable to release aqueous fluid from the exit chamber to a sclera of the eye.

2 . The shunt of claim 1 , wherein each of the two leaflets have a length that is two times a width of an inner lumen of the body.

3 . The shunt of claim 1 , wherein the end opposite the base of each of the leaflets has an end thickness that is ⅓ the base thickness.

4 . The shunt of claim 1 , wherein the two leaflets are operable to deform and separate from one another upon exposure to a predetermined amount of pressure from the aqueous fluid.

5 . The shunt of claim 1 , wherein at least one of the vein fluidic channel, the body, the valve, and/or the plurality of outlets is at least partially coated with at least one drug to be released into the aqueous fluid.

6 . The shunt of claim 5 , wherein the drug includes mitomycin-C.

7 . The shunt of claim 5 , wherein the drug is configured to be released over a predetermined period of time.

8 . The shunt of claim 7 , wherein the predetermined period of time is up to four weeks.

9 . The shunt of claim 1 , further comprising:

at least two retainers extending from the vein fluidic channel, the at least two retainers operable to maintain positioning of the vein fluidic channel.

10 . The shunt of claim 9 , wherein the at least two retainers are substantially circular and extend radially from the vein fluidic channel.

11 . The shunt of claim 9 , wherein the at least two retainers are positioned such that, when implanted, a first one of the at least two retainers is operable to be positioned on a trabecular meshwork surface of the eye and a second one of the at least two retainers is operable to be positioned on a scleral surface of the eye.

12 . The shunt of claim 1 , wherein a surface of at least one of the vein fluidic channel, the body, and/or the plurality of outlets operable to be placed, when implanted, on the eye is flat.

13 . The shunt of claim 1 , wherein at least one of the vein fluidic channel, the body, the valve, and/or the plurality of outlets is made of a bio-compatible material.

14 . The shunt of claim 13 , wherein the bio-compatible material includes a hydrogel.

15 . The shunt of claim 13 , wherein the bio-compatible material includes an acrylic hydrogel or a silicone hydrogel.

16 . A system comprising:

the shunt as recited in claim 1 ; and

a forceps operable to implant the shunt in the eye.

17 . The system of claim 16 , wherein the forceps include tips collectively forming a hollow body operable to receive, when the tips are in a closed configuration, the vein fluidic channel.

18 . The shunt of claim 1 , wherein the plurality of outlets comprise a plurality of pores in fluid communication with the exit chamber.

19 . The shunt of claim 1 , wherein the plurality of outlets comprise fluidic channels.